Key result
Oral enoximone improved symptom-limited exercise capacity by 43% at 6 weeks (p<0.01) and increased resting ejection fraction (p<0.02) in patients with chronic congestive heart failure.
Why the study?
Does oral enoximone improve exercise tolerance, ejection fraction, and symptoms in patients with chronic congestive heart failure?
Population
12 patients with chronic congestive heart failure (NYHA class II or III)
Comparison
Oral enoximone 150 mg three times daily added to… vs Placebo added to existing therapy for 6 weeks
Design
RCT, randomized crossover, double-blind
Follow-up
6 weeks per treatment
Authors
Loading...
Enoximone may enhance exercise tolerance in NYHA II-III HF; extends short-term PDE-III inhibitor data from hemodynamics to functional endpoints.
RCT (n=12)
Double-blind
Crossover
Does oral enoximone improve exercise tolerance, ejection fraction, and symptoms in patients with chronic congestive heart failure?
p-value: p=<0.01
In a small crossover trial, oral enoximone significantly improved exercise capacity, resting ejection fraction, and symptoms in patients with moderately severe congestive heart failure.
Choraria et al. (1987) conducted an RCT in chronic congestive heart failure (n=12). enoximone vs. placebo was evaluated on Symptom-limited exercise capacity (p=<0.01). Oral enoximone improved symptom-limited exercise capacity by 43% at 6 weeks (p<0.01) and increased resting ejection fraction (p<0.02) in patients with chronic congestive heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: